Respiratory

Although 2021 closes with a plentiful supply of COVID-19 vaccines and boosters, Americans continue to face challenges with the widespread Omicron variant and new testing hurdles.

Most people are aware of what triggers their chronic cough and how to temporarily suppress it, said Laurie Slovarp, PhD, CCC-SLP, associate professor in the School of Speech, Language, Hearing, and Occupational Sciences at University of Montana.

Chronic cough can be very debilitating to a patient's quality of life, explained Laurie Slovarp, PhD, CCC-SLP, associate professor in the School of Speech, Language, Hearing, and Occupational Sciences at University of Montana.

Participation in education sessions and frequent web-based monitoring predicted 1-year outcomes of asthma control for adolescents with partly controlled and uncontrolled asthma.

Peter Dicpinigaitis, MD, professor of medicine at the Albert Einstein College of Medicine and director of the Montefiore Cough Center, discusses what he and others have seen during the pandemic in patients with chronic cough who had COVID-19.

A small study found that patients with chronic cough saw improvements in symptoms following transcutaneous electrical nerve stimulation treatment, with minimal adverse effects.

A systematic review showed that a high fractional exhaled nitric oxide (FeNO) value before starting inhaled corticosteroid (ICS) therapy may be associated with higher response rates in patients with chronic cough.

Results of a retrospective study revealed potential markers of COVID-19 severity among those with chronic obstructive pulmonary disease, asthma, or chronic bronchitis.

Despite a relatively low response rate to acid suppression therapy to treat chronic cough, heartburn was a highly significant predictor of success.

The prognosis was worse in patients with basic dementia or Alzheimers disease as well as chronic obstructive pulmonary disease or asthma.

The study found that cough severity and cough-related quality of life were not related to the severity of bronchial hyperresponsiveness in nonsmoking adults with cough-variant asthma.

Most adverse events in trials of adenosine triphosphate (ATP) blockers for chronic cough are related to taste, which may inadvertently cause the studies to become unblinded to patients, and a way of measuring this to know the extent of the problem is needed, said Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.

An asthma risk score using 7 clinically relevant parameters evaluated in a pediatric Medicaid managed care population can stratify risk for following-year asthma hospitalization.

Multiple nationally representative surveys found that approximately 1 in 3 grade 12 students vaped cannabis in 2018 alone.

Medicare punished more than 2000 hospitals for high readmissions; cigarette sales increased in 2020 for the first time in 2 decades; a cheap antidepressant showed promise as an affordable oral treatment for COVID-19.

Peter Dicpinigaitis, MD, professor of medicine at the Albert Einstein College of Medicine, director of the Montefiore Cough Center, and editor-in-chief of LUNG, addresses gender and chronic cough

While sales have gone up, the research does not directly show whether there is an increase in people smoking cigarettes.

Patients whose pharmacy receives notification of their immunization gap have twice the odds of receiving immunizations compared with those whose pharmacy does not receive the notification.

Paulette Nyahay has a chronic cough unrelated to her asthma; here, she discusses how she works with multiple doctors and about how she discusses her condition with others.

New data show a decrease in COVID-19 deaths in the United States; long-term exposure to low levels of air pollution increases mortality risk; Moderna pressured to ramp up vaccine production.

Bronchial hyperresponsiveness may indicate the presence of cough-variant asthma in nonsmokers who have chronic cough, new research shows.

Peter Dicpinigaitis, MD, professor of medicine at the Albert Einstein College of Medicine, director of the Montefiore Cough Center, and editor-in-chief of LUNG, addresses the lack of approved treatments for chronic cough in the United States, current off-label remedies, and the prospect of future approvals.

Therapies that block adenosine triphosphate (ATP) can reduce the irritation that causes cough, and some currently being studied also don’t have taste side effects that can confound clinical trial results, explained Ron Eccles, BSc, PhD, DSc, emeritus profess at Cardiff University.

Analysis results highlight the efficacy of cough suppression therapy (CST) for those with chronic refractory cough and voice disorders.